Co-Authors
This is a "connection" page, showing publications co-authored by JEFFREY N MYERS and DAVID ROSENTHAL.
Connection Strength
1.523
-
Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol. 2022 Nov-Dec; 7(6):100989.
Score: 0.210
-
Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925.
Score: 0.195
-
Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2013 Oct; 35(10):1454-60.
Score: 0.108
-
Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck. 2013 Mar; 35(3):321-8.
Score: 0.103
-
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct 01; 27(28):4727-32.
Score: 0.087
-
Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol. 2006 Apr; 263(4):313-8.
Score: 0.067
-
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2023 09 01; 149(9):847-849.
Score: 0.057
-
Impact of Cancer Care Regionalization on Patient Volume. Ann Surg Oncol. 2023 Apr; 30(4):2331-2338.
Score: 0.055
-
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
Score: 0.052
-
Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
Score: 0.050
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.049
-
The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. Cancer. 2021 07 15; 127(14):2453-2464.
Score: 0.049
-
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
Score: 0.048
-
Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
Score: 0.048
-
Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
Score: 0.048
-
Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck. 2020 06; 42(6):1194-1201.
Score: 0.046
-
Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. Head Neck. 2020 06; 42(6):1179-1186.
Score: 0.046
-
Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
Score: 0.045
-
Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol. 2017 09; 72:90-97.
Score: 0.038
-
Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck. 2017 04; 39(4):633-638.
Score: 0.036
-
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e367-74.
Score: 0.026
-
Sonographic examination of the neck after definitive radiotherapy for node-positive oropharyngeal cancer. AJNR Am J Neuroradiol. 2011 Sep; 32(8):1532-8.
Score: 0.025
-
Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer. 2008 May 01; 112(9):2088-100.
Score: 0.020
-
ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol. 2005 Jul; 41(6):580-8.
Score: 0.016